[1]

刘长征, 王浩丹, 胡雅儿. 实验核医学与核药学. 北京: 人民卫生出版社. 1999: 218-249.
[2] Bigott-Hennkens HM, Dannoon S, Lewis MR, et al. In vitro receptor binding assays: general methods and considerations. Q J Nucl Med Mol Imaging, 2008, 52(3): 245-253.
[3] Pinyot A, Nikolovski Z, Bosch J, et al. On the use of cells or membranes for receptor binding: growth hormone secretagogues. Anal Biochem, 2010, 399(2): 174-181.  doi: 10.1016/j.ab.2010.01.003
[4] Kung MP, Choi SR, Hou C, et al. Selective binding of 2-[125I]iodonisoxetine to norepinephrine transporters in the brain. Nucl Med Biol, 2004, 31(5): 533-541.  doi: 10.1016/j.nucmedbio.2004.03.001
[5] Choi H, Choi SR, Zhou R, et al. Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. Acad Radiol, 2004, 11(9): 996-1004.  doi: 10.1016/j.acra.2004.04.018
[6] 高振霆, 罗海彬, 陈莉莉, 等. 顺十八碳四烯酸荧光探针法研究PPARγ与配体的结合亲和性. 中国科学B辑, 2004, 34(6): 441-448.
[7] Need AB, McKinzie JH, Mitch CH, et al. In vivo rat brain opioid receptor binding of LY255582 assessed with a novel method using LC/ MS/MS and the administration of three tracers simultaneously. Life Sci, 2007, 81(17-18): 1389-1396.  doi: 10.1016/j.lfs.2007.09.005
[8] Poon GM. Explicit formulation of titration models for isothermal titration calorimetry. Anal Biochem, 2010, 400(2): 229-236.  doi: 10.1016/j.ab.2010.01.025
[9] Cornelius P, Lee E, Lin W, et al.  Design, synthesis, and pharmacology of fluorescently labeled analogs of serotonin: application to screening of the 5-HT2C receptor[J]. J Biomol Screen, 2009, 14(4): 360-370.   doi: 10.1177/1087057109331804
[10] Goswami R, Ponde DE, Kung MP, et al.  Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters[J]. Nucl Med Biol, 2006, 33(6): 685-694.   doi: 10.1016/j.nucmedbio.2006.05.006
[11] Atack JR, Eng WS, Gibson RE, et al.  The plasma-occupancy relationship of the novel GABAA receptor benzodiazepine site ligand, alpha5IA, is similar in rats and primates[J]. Br J Pharmacol, 2009, 157(5): 796-803.   doi: 10.1111/j.1476-5381.2009.00216.x
[12] Zeng Z, O'Brien JA, Lemaire W, et al.  A novel radioligand for glycine transporter 1: characterization and use in autoradiographic and in vivo brain occupancy studies[J]. Nucl Med Biol, 2008, 35(3): 315-325.   doi: 10.1016/j.nucmedbio.2007.12.002
[13] Kecskés M, Kumar TS, Yoo L, et al.  Novel Alexa Fluor-488 labeled antagonist of the A(2A)adenosine receptor: Application to a fluorescence polarization-based receptor binding assay[J]. Biochem Pharmacol, 2010, 80(4): 506-511.   doi: 10.1016/j.bcp.2010.04.027
[14] 蒋心惠, 周岐新.  高效液相色谱法测定硫酸特布他林与红细胞膜表面β2肾上腺素受体结合量[J]. 分析化学, 2010, 38(3): 377-380.
[15] 蒋心惠, 杨俊卿, 周岐新.  沙丁胺醇与红细胞膜表面β2-肾上腺素受体结合量的高效液相色谱法测定[J]. 分析测试学报, 2010, 29(8): 837-840, 845.   doi: 10.3969/j.issn.1004-4957.2010.08.016
[16] Höfner G, Wanner KT.  Competitive binding assays made easy with a native marker and mass spectrometric quantification[J]. Angew Chem Int Ed Engl, 2003, 42(42): 5235-5237.   doi: 10.1002/anie.200351806
[17] Zepperitz C, Höfner G, Wanner KT.  MS-binding assays: Kinetic, saturation, and competitive experiments based on quantitation of bound marker as exemplified by the GABA transporter mGAT1[J]. ChemMed-Chem, 2006, 1(2): 208-217.   doi: 10.1002/cmdc.200500038
[18] Höfner G, Merkel D, Wanner KT.  MS binding assays-with MALDI toward high throughput[J]. ChemMedChem, 2009, 4(9): 1523-1528.   doi: 10.1002/cmdc.200900201
[19] Emonds KM, Swinnen JV, Mortelmans L, et al.  Molecular imaging of prostate cancer[J]. Methods, 2009, 48(2): 193-199.   doi: 10.1016/j.ymeth.2009.03.021
[20] Hou C, Tu Z, Mach R, et al.  Characterization of a novel iodinated sigma-2 receptor ligand as a cell proliferation marker[J]. Nucl Med Biol, 2006, 33(2): 203-209.   doi: 10.1016/j.nucmedbio.2005.10.001
[21] Oya S, Choi SR, Kung MP, et al.  5-Chloro-2-(2'-((dimethylamino)methyl)-4'-iodophenylthio)benzenamine: a new serotonin transporter ligand[J]. Nucl Med Biol, 2007, 34(2): 129-139.   doi: 10.1016/j.nucmedbio.2006.12.002
[22] Lakshmi B, Kung MP, Lieberman B, et al.  (R)-N-Methyl-3-(3-(125)I-pyridin-2-yloxy)-3-phenylpropan-1-amine: a novel probe for norepinephrine transporters[J]. Nucl Med Biol, 2008, 35(1): 43-52.   doi: 10.1016/j.nucmedbio.2007.08.007
[23] Bourdier T, Poisnel G, Dhilly M, et al.  Synthesis and biological evaluation of N-substituted quinolinimides, as potential ligands for in vivo imaging studies of delta-opioid receptors[J]. Bioconjug Chem, 2007, 18(2): 538-548.   doi: 10.1021/bc0602836
[24] Li J, Fish RL, Cook SM, et al.  Comparison of in vivo and ex vivo [3H]flumazenil binding assays to determine occupancy at the benzodiazepine binding site of rat brain GABAA receptors[J]. Neuropharmacology, 2006, 51(1): 168-172.   doi: 10.1016/j.neuropharm.2006.03.020
[25] Barth VN, Chernet E, Martin LJ, Need AB, et al.  Comparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measured using radiolabeled or nonlabeled raclopride tracer[J]. Life Sci, 2006, 78(26): 3007-3012.   doi: 10.1016/j.lfs.2005.11.031
[26] Zhu L, Liu J, Kung HF.  Synthesis and evaluation of 2-amino-dihydrotetrabenzine derivatives as probes for imaging vesicular monoamine transporter-2[J]. Bioorg Med Chem Lett, 2009, 19(17): 5026-5028.   doi: 10.1016/j.bmcl.2009.07.048
[27] Stadalnik RC, Vera DR.  The evolution of (99m)Tc-NGA as a clinically useful receptor-binding radiopharmaceutical[J]. Nucl Med Biol, 2001, 28(5): 499-503.   doi: 10.1016/S0969-8051(01)00219-0